{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/prescribing-information/haloperidol/","result":{"pageContext":{"chapter":{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol","depth":2,"htmlHeader":"<!-- begin field 34a97556-ab37-4c66-b1d0-d43e184988fe --><h2>Haloperidol</h2><!-- end field 34a97556-ab37-4c66-b1d0-d43e184988fe -->","summary":"","htmlStringContent":"<!-- begin item f5f11513-f0a2-46bb-9d2a-5480d83dc105 --><!-- begin field a05de895-3ba1-4521-b730-a44d4892dd9a --><ul><li><strong>Haloperidol should only be used on the advice of a specialist for the treatment of challenging behaviour associated with dementia. </strong><ul><li>Short-term treatment with haloperidol (off-label use) may be suggested for immediate management of violence, aggression, or extreme agitation in people with dementia when non-pharmacological measures have failed and the person poses a risk to themselves or others. </li><li>The aim of the treatment is to calm the person and reduce agitation or aggression, not to sedate.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE Pathway, 2016</a>]</p><!-- end field a05de895-3ba1-4521-b730-a44d4892dd9a --><!-- end item f5f11513-f0a2-46bb-9d2a-5480d83dc105 -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1d87cb5e-eb0c-5380-9286-2a662968d4ae","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field d32cb5fd-c13a-4998-a82e-908f74b25a00 --><h3>What dose of haloperidol is usually prescribed and what monitoring is required?</h3><!-- end field d32cb5fd-c13a-4998-a82e-908f74b25a00 -->","summary":"","htmlStringContent":"<!-- begin item 7dbb74a4-c817-4989-b1d2-f50d8ab1dd30 --><!-- begin field 387b574e-2f15-4448-a9e8-a66f97e5014d --><ul><li><strong>The use of oral haloperidol for the treatment of challenging behaviour associated with dementia is off-label and it should </strong><em><strong>only</strong></em><strong> be prescribed on the advice of a specialist, who should specify the dose and duration of treatment.</strong> As a general guide:<ul><li>Treatment should start at the lowest possible dose and be slowly titrated up, if necessary.</li><li>The British National Formulary (BNF) suggests an initial dose of 0.75–1.5 mg by mouth 2–3 times daily, for agitation and restlessness in the elderly.</li><li>One-to-one care of the person should be available while the dose is titrated in a controlled and safe manner.</li><li>The person should be reviewed regularly and haloperidol discontinued as soon as possible.</li></ul></li><li>An electrocardiogram (ECG) is recommended before initiation of haloperidol, particularly if cardiovascular risk factors, or a history of cardiovascular disease are present. ECG and blood pressure monitoring during treatment with haloperidol is advised.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE Pathway, 2016</a>]</p><!-- end field 387b574e-2f15-4448-a9e8-a66f97e5014d --><!-- end item 7dbb74a4-c817-4989-b1d2-f50d8ab1dd30 -->","subChapters":[]},{"id":"21fc786f-6dd7-5124-b8fa-fc767291d013","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 69c8244e-1db5-4e5c-b53a-512aa172b118 --><h3>What are the possible adverse effects of haloperidol?</h3><!-- end field 69c8244e-1db5-4e5c-b53a-512aa172b118 -->","summary":"","htmlStringContent":"<!-- begin item 2f2872f2-5e28-4418-afab-714865466c0f --><!-- begin field 6c280003-fd28-4933-8c37-e8e77213c5a9 --><ul><li><strong>Adverse effects of haloperidol may include:</strong><ul><li>Extrapyramidal symptoms (such as parkinsonism, dystonic reactions, and akathisia) — acute dystonias may occur early in treatment and irreversible tardive dyskinesia may develop during treatment, or after the drug has been discontinued.</li><li>Cardiac effects — QT prolongation and cases of sudden death have been reported in people taking haloperidol. <ul><li>Dose-related hypotension can occur, particularly in elderly people, and may lead to falls.</li></ul></li><li>Neuroleptic malignant syndrome (NMS) — a rare but life-threatening adverse effect that can occur with any antipsychotic.<ul><li>Symptoms and signs include hyperthermia, muscle rigidity, autonomic instability, fluctuating consciousness, myoglobinuria (rhabdomyolysis) and acute renal failure.</li><li>If a person develops signs and symptoms of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, emergency medical treatment is needed. The mortality rate without treatment is 20%.</li></ul></li><li>Hormonal effects — these include hyperprolactinaemia, which may cause galactorrhoea and gynaecomastia. Very rare cases of hypoglycaemia and syndrome of inappropriate antidiuresis (SIAD) have been reported.</li><li>Gastrointestinal effects — these include dry mouth, constipation, nausea, vomiting, loss of appetite, weight changes, and dyspepsia.</li><li>Psychiatric effects — these include agitation, insomnia, and depression.</li><li>Convulsions — haloperidol may trigger seizures (the higher the dose, the greater the risk).</li><li>Urinary retention.</li><li>Visual disturbance — this includes blurred vision and very rarely, precipitation of angle-closure glaucoma.</li><li>Venous thromboembolism — cases of pulmonary embolism and deep vein thrombosis have been reported.</li><li>Others — drowsiness, apathy, dizziness, headache and, confusion; dyspnoea, bronchospasm, and laryngeal oedema; hypoglycaemia; hypertension; sweating; nasal congestion; blood dyscrasias (such as agranulocytosis and leucopenia); Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitization, contact sensitization and rashes; abnormal liver function tests and jaundice (including cholestatic); corneal and lens opacities; and purplish pigmentation of the skin, cornea, conjunctiva, and retina.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field 6c280003-fd28-4933-8c37-e8e77213c5a9 --><!-- end item 2f2872f2-5e28-4418-afab-714865466c0f -->","subChapters":[]},{"id":"eee310e8-1a91-5d13-a702-9f2da9f80e15","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5782cfdb-2154-44c3-b268-5d262128a283 --><h3>What are the contraindications and cautions with haloperidol?</h3><!-- end field 5782cfdb-2154-44c3-b268-5d262128a283 -->","summary":"","htmlStringContent":"<!-- begin item 95a9eb43-08c7-45ba-918b-f2c912616c06 --><!-- begin field 98017c1f-b706-4ef3-828a-e9bd6f4329a5 --><p><strong>Do not prescribe haloperidol if:</strong></p><ul><li>The person has (or is suspected of having):<ul><li>Parkinson's disease, lesions of the basal ganglia, or Lewy body dementia.</li><li>Central nervous system depression or neuromuscular weakness (such as myasthenia gravis) or they are in a comatose state.</li><li>A phaeochromocytoma.</li><li>A cardiac disorder, such as:<ul><li>QT interval prolongation.</li><li>Recent acute myocardial infarction.</li><li>Uncompensated heart failure or second- or third-degree heart block.</li><li>Arrhythmias treated with class IA antiarrhythmic drugs (for example disopyramide, procainamide, or quinidine) or class III antiarrhythmic drugs (for example amiodarone or sotalol), or a history of ventricular arrhythmia or Torsades de pointes.</li><li>Bradycardia.</li></ul></li><li>Uncorrected hypokalaemia — can increase the risk of cardiac arrhythmias.</li><li>Known hypersensitivity to haloperidol.</li></ul></li><li>The person is taking <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/prescribing-information/haloperidol/#drug-interactions\">certain drugs</a> such as those that prolong the QT interval, cause hypokalaemia, or increase haloperidol levels.</li></ul><p><strong>Prescribe haloperidol with caution to people with:</strong></p><ul><li>Epilepsy (or conditions predisposing to seizures, such as alcohol withdrawal and brain damage).</li><li>Depression.</li><li>Subarachnoid haemorrhage.</li><li>Prostatic hypertrophy.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Severe respiratory disease.</li><li>Hepatic impairment or a history of jaundice.</li><li>Renal impairment.</li><li>Blood dyscrasias.</li><li>Metabolic disturbances, such as hypokalaemia, hypocalcaemia, or hypomagnesaemia.</li><li>Hyperthyroidism.</li><li>Arteriosclerosis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">MHRA, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">MHRA, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field 98017c1f-b706-4ef3-828a-e9bd6f4329a5 --><!-- end item 95a9eb43-08c7-45ba-918b-f2c912616c06 -->","subChapters":[]},{"id":"9de41207-31fb-5358-b023-c236cf4ee13c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 31d3c9c1-8fdc-4f0f-a9e7-64d63dbc4895 --><h3>What are the possible drug interactions with haloperidol?</h3><!-- end field 31d3c9c1-8fdc-4f0f-a9e7-64d63dbc4895 -->","summary":"","htmlStringContent":"<!-- begin item 600e40c1-322c-465b-b3f6-f5c7d0c3976d --><!-- begin field f7b51d04-8247-4d04-b22c-136647293345 --><ul><li><strong>Haloperidol may interact with:</strong><ul><li><strong>Antibiotic drugs</strong> — there is an increased risk of ventricular arrhythmias when haloperidol is given with moxifloxacin. Avoid concomitant use.</li><li><strong>Anticonvulsant drugs </strong>— rarely, an encephalopathy-like syndrome has been reported in people taking a combination of lithium and haloperidol. In addition, there is an increased risk of extrapyramidal adverse effects and potential neurotoxicity when haloperidol is given with lithium. The dose of the anti-convulsant drugs may need to be increased to compensate for the lowered seizure threshold associated with haloperidol use.</li><li><strong>Antidepressants </strong>— haloperidol inhibits the metabolism of tricyclic antidepressants and increases their plasma levels. Avoid concomitant use.</li><li><strong>Anticoagulant drugs</strong> — antagonism of the effect of phenindione has been reported following concurrent treatment with lorazepam.</li><li><strong>Antimalarial drugs</strong> — there is an increased risk of ventricular arrhythmias when haloperidol is given with mefloquine or quinine. Avoid concomitant use.</li><li><strong>Antiretroviral drugs</strong> — there is an increased risk of ventricular arrhythmias when haloperidol is given with saquinavir. Avoid concomitant use.</li><li><strong>Central nervous system (CNS) depressants</strong> — concurrent use of haloperidol with drugs that depress the CNS (such as alcohol, hypnotics, sedatives, or strong analgesics) can increase CNS depression.</li><li><strong>Drugs known to cause electrolyte imbalance</strong> — concurrent use with haloperidol may increase the risk of ventricular arrhythmias. Avoid concurrent use. In particular, diuretics that can cause hypokalaemia should be avoided. If necessary, potassium-sparing diuretics are preferred.</li><li><strong>Drugs known to prolong the QT interval</strong> — haloperidol may increase the risk of ventricular arrthymias, including Torsade de pointes, when given with drugs that prolong the QT interval (for example anti-arrhythmics [such as amiodarone and sotalol], certain antimicrobials [such as erythromycin], antidepressants [such as amitriptyline, citalopram, and escitalopram], other neuroleptics [such as phenothiazines and sertindole], certain antihistamines [such as terfenadine], and mefloquine). Avoid concomitant use.<ul><li>Amiodarone has a long half-life; there is a potential for drug interactions to occur several weeks (or even months) after treatment has been stopped.</li><li>Co-administration of citalopram and escitalopram with haloperidol is contraindicated.</li></ul></li><li><strong>Enzyme-inducing drugs</strong> (such as carbamazepine, phenobarbital, rifampicin) — concurrent use with haloperidol can cause a significant reduction in plasma levels of haloperidol.</li><li><strong>Enzyme inhibiting drugs</strong> — drugs that inhibit glucuronidation or the cytochrome P450 enzyme system or those that decrease CYP 2D6 enzyme activity (for example itraconazole, quinidine, fluvoxamine, fluoxetine, sertraline, paroxetine, chlorpromazine, and promethazine) may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation. Concurrent use (especially with fluoxetine) should be with caution.</li><li><strong>Sympathomimetic drugs</strong> — haloperidol may antagonize the action of adrenaline and other sympathomimetic drugs.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">MHRA, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]</p><!-- end field f7b51d04-8247-4d04-b22c-136647293345 --><!-- end item 600e40c1-322c-465b-b3f6-f5c7d0c3976d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}